RADL3:BMFBOVESPARaia Drogasil S.A. Analysis

Raia Drogasil trades at R$23.52, comfortably above its 20‑day SMA of 25.23 and 50‑day SMA of 24.92, indicating a short‑term bullish bias despite a bearish MACD histogram. The RSI sits at 36, hinting at modest downside momentum and potential oversold conditions near the identified support of R$23.05. Volume is on an increasing trend, supporting the price’s resilience above support while the 30‑day volatility of roughly 33% underscores notable price swings. Relative to peers, the stock’s trailing PE of 30.15 exceeds the industry average of 25.11, and the DCF‑derived fair value of R$5.08 suggests a substantial valuation gap. Revenue growth remains robust at 20% year‑over‑year, yet operating margins are thin (6.2%) and debt‑to‑equity is high at 120%, adding balance‑sheet pressure. The dividend yield of 1.61% with a payout ratio under 50% appears sustainable given positive free cash flow. Overall, the stock presents a mixed picture: strong top‑line momentum and dividend coverage counterbalanced by elevated valuation, leverage, and market volatility.